Four approved IO agents split US first-line NSCLC into three PD-L1 cohorts, with pembrolizumab holding an estimated 52% share ahead of its 2028 patent expiry.
Four approved IO agents have divided the first-line patient pool into distinct biomarker cohorts — each with a different dominant agent, different clinical precedents, and different payer coverage criteria. Pembrolizumab controls the PD-L1 ≥50% monotherapy setting through five years of clinical and commercial precedent. Combination regimens have set a different standard below that threshold. These cohorts are not interchangeable, and a single commercial strategy will not address both.
US payer coverage criteria for IO agents in NSCLC were written around the early KEYNOTE and CheckMate trials. New entrants are evaluated against those precedents — not against their own trial designs. The evidence a payer will require at your approval is already visible in the coverage policies for existing agents. The window to shape that conversation is 12 to 18 months pre-approval, not at launch.
Below, we map that landscape and frame the decisions your commercial team needs to make before strategy is locked.
Exhibit 3 — Competitive landscape, NSCLC first line.
| Agent (Sponsor) | PD-L1 Threshold | Approved 1L Setting | Pivotal Trial | mPFS | mOS | US Coverage | Share Est. |
|---|---|---|---|---|---|---|---|
| PembrolizumabKeytruda · Merck | ≥50% (mono) / ≥1% (combo) | 1L monotherapy (high PD-L1); 1L chemo combo all histologies | KEYNOTE-024, 189, 407 | 16.7 mo (mono) | 26.3 mo (mono) | Broad | ~52% |
| Nivolumab + IpilimumabOpdivo + Yervoy · BMS | Any (TMB signal) | 1L IO-IO doublet all histologies | CheckMate-9LA, 227 | 6.7 mo | 15.6 mo | Broad | ~18% |
| AtezolizumabTecentriq · Roche/Genentech | Any (SP142 IHC) | 1L combination regimens | IMpower110, IMpower150 | 7.1 mo | 20.2 mo (high PD-L1) | Restricted | ~8% |
| DurvalumabImfinzi · AstraZeneca | Stage III: any / 1L: any (LAURA) | Stage III post-CRT consolidation; emerging 1L | PACIFIC, LAURA (2024) | 16.9 mo PFS2 | 47.5 mo (PACIFIC) | Broad (S-III) / Emerging (1L) | ~12% |
Sources: FDA prescribing information (pembrolizumab, nivolumab + ipilimumab, atezolizumab, durvalumab). KEYNOTE-024: Reck et al., NEJM 2016 · PMID 27718847. KEYNOTE-189: Gandhi et al., NEJM 2018 · PMID 29658856. KEYNOTE-407: Paz-Ares et al., NEJM 2018 · PMID 30280635. CheckMate-9LA: Reck et al., Lancet Oncol 2021 · PMID 34126067. CheckMate-227: Hellmann et al., NEJM 2018 · PMID 29658845. IMpower110: Spigel et al., NEJM 2021 · PMID 34280284. IMpower150: Socinski et al., NEJM 2018 · PMID 29863955. PACIFIC: Antonia et al., NEJM 2017 · PMID 28885881. LAURA: Lu et al., NEJM 2024. Prescribing share estimates derived from IQVIA MIDAS analogs; cited in full source annex.
Five commercial questions. Each section is built to answer one of them.
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Patient funnel from incidence to IO-eligible · PD-L1 cohort breakdown · five-year projection with testing-rate sensitivity
Delivers
- Agent map by cohort · pivotal trial comparison (OS · PFS · ORR) · estimated prescribing share
Delivers
- Coverage criteria by agent · prior authorisation requirements · gap analysis vs. your trial design
Delivers
- Non-responder and progression-after-IO cohort mapping · biomarker gap analysis · MOA alignment assessment
Delivers
- Three-scenario share model · ranked assumption drivers · revenue sensitivity table
Scoped to your asset, your proposed label, and your target cohort — not the market in aggregate.
Scope Your WorkWhat's inside
- Three decisions answered for your team, three confirmed open, and the commercial posture recommended before your first strategy review
- Pre-launch actions by function (commercial, medical affairs, market access), in order of urgency
- What secondary research can resolve now vs. what requires primary investigation
- Which patients are IO-eligible — the molecular exclusion funnel that defines the real addressable pool
- PD-L1 testing penetration and the distribution gap between diagnosed NSCLC and biomarker-stratified patients
- The epidemiological assumptions your commercial team will be challenged on in the first strategy review
- Bottom-up build: incidence → systemic-eligible → IO-eligible by PD-L1 cohort and line of therapy
- Five-year projection with testing-rate and staging-mix sensitivity — where the model breaks
- The three assumptions that drive 80% of the variance in the addressable patient estimate
- Which agents hold which cohorts, on what clinical evidence, and what it would take to move prescribing share
- Trial-level analytical stack: OS · PFS · ORR across KEYNOTE, CheckMate, IMpower, PACIFIC, LAURA
- Pipeline entrants and pembrolizumab biosimilar entry — what the landscape looks like post-2028 LoE
- Coverage criteria by agent — what broad, restricted, and step-therapy gated look like for IO agents in practice
- The evidence standard payers will apply to your approval: not your trial design, theirs
- Gap analysis — where your clinical package strengthens the access case and where it does not
- The 20 investigators who publish, present, and set local practice patterns in IO NSCLC — by geography
- NCCN Thoracic panel positions and what the field currently believes about new mechanism entry
- Where prescribing influence concentrates and where new entrants have found early traction
- Three patient capture scenarios (conservative, base, aggressive), built by cohort, not in aggregate
- The five inputs that drive variance: testing penetration, label scope, payer timeline, competitive response, switch rate
- Y1 · Y3 · Y5 patient volume and revenue by cohort — with the lever each decision-maker controls
- Evidence gaps secondary research cannot close — and the primary work your team would need to commission
- Payer conversations that must begin 12–18 months pre-approval to avoid formulary delay at launch
- Decisions contingent on label scope, trial outcomes, or competitive moves not yet visible
Included with every brief
Every figure is live-sourced before delivery. If a number cannot be verified, it does not appear.
Prepared by MoatRx analysts.
The IO competitive landscape is a field where AI confidently reproduces outdated trial data, superseded payer policies, and retracted subgroup analyses. AXLRx uses none of its own memory as a source. Every figure your team receives is verified against a live document at the time of writing.
A wrong number in front of your payer or your leadership team is not recoverable in the same meeting.
- Every claim cited to a live PMID, ClinicalTrials.gov ID, or URL at point of writing — uncited claims are dropped, not estimated
- PubMed metadata fetched live during authoring — model memory produces incorrect author and journal data even on correct PMIDs
- Numeric cross-check: the specific figure must appear in the cited source, not merely be consistent with its topic
- Independent audit pass after generation — broken links, unsourced claims, and numeric inconsistencies flagged before delivery
- Drop gate: any figure that cannot clear the above is removed. No confidence tiers. No exceptions.
Frequently asked questions
Tell us your asset. Your team has the intelligence in 72 hours.
We build from your asset’s clinical profile — mechanism, biomarker strategy, proposed label, and target cohort. Scope confirmation takes one call.
Drug, mechanism, proposed indication, target cohort, geography. Five minutes via the intake form.
We confirm scope with your team, clarify any ambiguities, and lock delivery timing. One call or email exchange.
PDF intelligence document, Excel model, and optional executive deck — with a 30-minute readout call included.